ArticleJournal, genetic engineering & biotechnology2026
Phosphosite-specific co-regulation networks of MELK kinase: insights from integrative global phosphoproteomes.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal embryonic leucine zipper kinase (MELK) is a serine/threonine kinase frequently overexpressed in aggressive cancers, yet the precise mechanisms governing its activation and signaling specificity remain poorly understood. Here, we present the first phosphosite-resolved co-regulation atlas of MELK through integrative meta-analysis of 3,825 global human phosphoproteomics datasets. Three phosphosites-S356, S505, and S529-emerge as dominant regulatory nodes, exhibiting high detection frequency and distinct co-regulation patterns. S356 and S505 form a tightly coupled proliferative-mitotic axis controlled by convergent Mitogen-Activated Protein Kinase Kinase (MAPK), Ribosomal S6 Kinase (RSK), Calcium/Calmodulin-dependent protein Kinase (CaMK), Hippo-related, and spindle-checkpoint kinases (NIMA-related kinase 4 (NEK4), Threonine Tyrosine Kinase/Monopolar Spindle 1 Kinase (TTK/MPS1)), whereas S529 functions as a partially antagonistic stress- and polarity-responsive module. Marker of Proliferation Ki-67 (MKI67) phosphosites co-vary with all three MELK sites across virtually all proliferative contexts, establishing a direct mechanistic link between MELK activity and clinical proliferation markers. Extensive networks of co-regulated upstream kinases, phosphatases, binary interactors, and downstream substrates further reveal functional segregation: S356/S505 primarily drive cell-cycle progression and chromatin organization, while S529 integrates calcium, metabolic, and cytoskeletal polarity signals. Kaplan-Meier survival analysis across TCGA cohorts further revealed that high expression of MELK, MKI67, and the mitotic checkpoint kinase TTK consistently predicts poor overall and disease-free survival in lung adenocarcinoma and hepatocellular carcinoma, reinforcing the strong phosphodynamic coupling between MELK activity and clinical proliferation markers. By demonstrating that MELK signaling is orchestrated through modular, site-specific phosphorylation logic rather than total protein abundance, this work establishes a new paradigm for understanding and therapeutically targeting this enigmatic oncogenic kinase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.